In keeping with the retention of VLA-4 activation, CLL cells treated in vitro with ibrutinib were still able to increase their adhesion levels on VCAM-1 upon anti-IgM stimulation to an extent similar to that observed in ibrutinib-naive cells (Fig. 1 I). This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.